Literature DB >> 9185242

Time-scale of interleukin-6, myeloid related proteins (MRP), C reactive protein (CRP), and endotoxin plasma levels during the postoperative acute phase reaction.

D Berger1, E Bölke, M Seidelmann, H G Beger.   

Abstract

During goitre surgery (25 patients) and after major abdominal surgery (52 patients), we studied the plasma levels of endotoxin, interleukin-6 (IL-6), C reactive protein (CRP), and the so called myeloid-related proteins (MRP), MRP8, MRP14, and the heterocomplex of both single proteins, MRP8/MRP14 in three intervals: pre-, intra-, and postoperative. We observed that CRP levels began to increase on the first postoperative day, reaching a maximum on day 2 (median levels of 185 mg/L after major surgery and 77 mg/L after goitre surgery). IL-6 levels peaked at the end of the operation, remaining elevated for 6 h following abdominal surgery (299 pg/mL) and peaked on day 1 after goitre surgery (63 pg/mL). An increase in MRP8/MRP14 levels began toward the end of abdominal surgery, and maximum levels were recorded until 5 days after the operation (5,695 micrograms/L). Plasma levels were significantly elevated 2 and 6 h after minor surgery (3,619 micrograms/L), while no changes were observed in the plasma levels of MRP8 and MRP14. Evidence of significant endotoxemia was found after the induction of anesthesia in the abdominal surgery group (.13 endotoxin units (EU)/mL) and after skin incision (.07 EU/mL) in the thyroid surgery group. The observed time sequence, starting with the release of bacterial products at an early stage, followed by the secondary stimulation of factors inherent to the acute phase led us to conclude that certain bacterial compounds, probably deriving from the gastrointestinal tract, trigger the postoperative acute phase reaction and are responsible for the activation of monocytes/macrophages and granulocytes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9185242     DOI: 10.1097/00024382-199706000-00006

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  7 in total

1.  Influence of major surgery on the mannan-binding lectin pathway of innate immunity.

Authors:  H Ytting; I J Christensen; L Basse; J Lykke; S Thiel; J C Jensenius; H J Nielsen
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

2.  A mouse model of severe halothane hepatitis based on human risk factors.

Authors:  Christine M Dugan; Allen E MacDonald; Robert A Roth; Patricia E Ganey
Journal:  J Pharmacol Exp Ther       Date:  2010-02-02       Impact factor: 4.030

3.  Influence of surgical intervention in the immune response of severely injured patients.

Authors:  Sascha Flohé; Sven Lendemans; Fritz-Ulrich Schade; Ernst Kreuzfelder; Christian Waydhas
Journal:  Intensive Care Med       Date:  2003-11-07       Impact factor: 17.440

Review 4.  Immune response of severely injured patients--influence of surgical intervention and therapeutic impact.

Authors:  S Flohé; S B Flohé; F U Schade; C Waydhas
Journal:  Langenbecks Arch Surg       Date:  2007-06-29       Impact factor: 3.445

5.  Serum Level of HMGB1 Protein and Inflammatory Markers in Patients with Secondary Peritonitis: Time Course and the Association with Clinical Status.

Authors:  Ljiljana Milić; Ilijana Grigorov; Slobodan Krstić; Miljan S Ćeranić; Bojan Jovanović; Jelena Stevanović; Predrag Peško
Journal:  J Med Biochem       Date:  2017-01-25       Impact factor: 3.402

6.  Systematic Review and Meta-Analysis of the Benefit and Safety of Preoperative Administration of Steroid in Patients Undergoing Liver Resection.

Authors:  Lingpeng Yang; Zifei Zhang; Junjie Kong; Wentao Wang
Journal:  Front Pharmacol       Date:  2019-11-28       Impact factor: 5.810

Review 7.  Inflammatory mediators in intra-abdominal sepsis or injury - a scoping review.

Authors:  Zhengwen Xiao; Crystal Wilson; Helen Lee Robertson; Derek J Roberts; Chad G Ball; Craig N Jenne; Andrew W Kirkpatrick
Journal:  Crit Care       Date:  2015-10-27       Impact factor: 9.097

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.